- Home
- FUSB vs SNTI Comparison
FUSB vs SNTI Comparison
Compare FUSB & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- SNTI
- Stock Information
- Founded
- FUSB 1952
- SNTI 2016
- Country
- FUSB United States
- SNTI United States
- Employees
- FUSB N/A
- SNTI N/A
- Industry
- FUSB Major Banks
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- FUSB Finance
- SNTI Health Care
- Exchange
- FUSB Nasdaq
- SNTI Nasdaq
- Market Cap
- FUSB 72.6M
- SNTI 85.3M
- IPO Year
- FUSB N/A
- SNTI N/A
- Fundamental
- Price
- FUSB $12.85
- SNTI $2.17
- Analyst Decision
- FUSB
- SNTI Strong Buy
- Analyst Count
- FUSB 0
- SNTI 2
- Target Price
- FUSB N/A
- SNTI $8.50
- AVG Volume (30 Days)
- FUSB 2.3K
- SNTI 342.2K
- Earning Date
- FUSB 07-23-2025
- SNTI 08-12-2025
- Dividend Yield
- FUSB 2.20%
- SNTI N/A
- EPS Growth
- FUSB N/A
- SNTI N/A
- EPS
- FUSB 1.28
- SNTI N/A
- Revenue
- FUSB $38,449,000.00
- SNTI N/A
- Revenue This Year
- FUSB N/A
- SNTI N/A
- Revenue Next Year
- FUSB N/A
- SNTI $150.00
- P/E Ratio
- FUSB $9.95
- SNTI N/A
- Revenue Growth
- FUSB N/A
- SNTI N/A
- 52 Week Low
- FUSB $8.75
- SNTI $1.52
- 52 Week High
- FUSB $14.30
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- FUSB 65.47
- SNTI 33.12
- Support Level
- FUSB $12.46
- SNTI $2.56
- Resistance Level
- FUSB $12.75
- SNTI $3.40
- Average True Range (ATR)
- FUSB 0.10
- SNTI 0.43
- MACD
- FUSB 0.05
- SNTI -0.09
- Stochastic Oscillator
- FUSB 100.00
- SNTI 2.33
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.